Jeffrey L. Dage

14.7k total citations · 16 hit papers
82 papers, 6.1k citations indexed

About

Jeffrey L. Dage is a scholar working on Physiology, Psychiatry and Mental health and Molecular Biology. According to data from OpenAlex, Jeffrey L. Dage has authored 82 papers receiving a total of 6.1k indexed citations (citations by other indexed papers that have themselves been cited), including 60 papers in Physiology, 54 papers in Psychiatry and Mental health and 15 papers in Molecular Biology. Recurrent topics in Jeffrey L. Dage's work include Alzheimer's disease research and treatments (58 papers), Dementia and Cognitive Impairment Research (54 papers) and Functional Brain Connectivity Studies (7 papers). Jeffrey L. Dage is often cited by papers focused on Alzheimer's disease research and treatments (58 papers), Dementia and Cognitive Impairment Research (54 papers) and Functional Brain Connectivity Studies (7 papers). Jeffrey L. Dage collaborates with scholars based in United States, Sweden and United Kingdom. Jeffrey L. Dage's co-authors include Oskar Hansson, Niklas Mattsson, Sebastian Palmqvist, Erik Stomrud, Kaj Blennow, Shorena Janelidze, Xiyun Chai, Henrik Zetterberg, Ruben Smith and Nicholas K. Proctor and has published in prestigious journals such as Nature Medicine, Nature Communications and Neuron.

In The Last Decade

Jeffrey L. Dage

68 papers receiving 6.0k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Plasma P-tau181 in Alzheimer’s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer’s dementia

2020 765 citations Shorena Janelidze, Niklas Mattsson et al. Nature Medicine profile →
Plasma phospho‐tau181 increases with Alzheimer's disease clinical severity and is associated with tau‐ and amyloid‐positron emission tomography

2018 413 citations Michelle M. Mielke, Xiyun Chai et al. Alzheimer s & Dementia profile →
Prediction of future Alzheimer’s disease dementia using plasma phospho-tau combined with other accessible measures

2021 324 citations Sebastian Palmqvist, Nicholas Cullen et al. Nature Medicine profile →
Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer’s disease

2020 292 citations Shorena Janelidze, Erik Stomrud et al. Nature Communications profile →
Performance of plasma phosphorylated tau 181 and 217 in the community

2022 246 citations Michelle M. Mielke, Jeffrey L. Dage et al. Nature Medicine profile →
Plasma p‐tau181, p‐tau217, and other blood‐based Alzheimer's disease biomarkers in a multi‐ethnic, community study

2021 231 citations Adam M. Brickman, Jennifer J. Manly et al. Alzheimer s & Dementia profile →
Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease

2019 230 citations Sebastian Palmqvist, Erik Stomrud et al. profile →
Associations of Plasma Phospho-Tau217 Levels With Tau Positron Emission Tomography in Early Alzheimer Disease

2020 222 citations Shorena Janelidze, Ruben Smith et al. profile →
Aβ deposition is associated with increases in soluble and phosphorylated tau that precede a positive Tau PET in Alzheimer’s disease

2020 217 citations Niklas Mattsson, Shorena Janelidze et al. profile →
Blood biomarkers for Alzheimer’s disease in clinical practice and trials

2023 196 citations Oskar Hansson, Kaj Blennow et al. Nature Aging profile →
Blood‐based biomarkers for Alzheimer's disease

2021 196 citations Antoine Leuzy, Niklas Mattsson et al. profile →
Plasma biomarkers of Alzheimer’s disease improve prediction of cognitive decline in cognitively unimpaired elderly populations

2021 171 citations Nicholas Cullen, Antoine Leuzy et al. Nature Communications profile →
Comparison of Plasma Phosphorylated Tau Species With Amyloid and Tau Positron Emission Tomography, Neurodegeneration, Vascular Pathology, and Cognitive Outcomes

2021 146 citations Michelle M. Mielke, Ryan D. Frank et al. profile →
Association of Donanemab Treatment With Exploratory Plasma Biomarkers in Early Symptomatic Alzheimer Disease

2022 138 citations Jeffrey L. Dage, Sergey Shcherbinin et al. profile →
Confounding factors of Alzheimer's disease plasma biomarkers and their impact on clinical performance

2022 127 citations Shorena Janelidze, Nicholas Cullen et al. Alzheimer s & Dementia profile →
Blood-based biomarkers for Alzheimer’s disease: Current state and future use in a transformed global healthcare landscape

2023 121 citations Harald Hampel, Yan Hu et al. Neuron profile →

Peers

Countries citing papers authored by Jeffrey L. Dage

Since Specialization

Citations

This map shows the geographic impact of Jeffrey L. Dage's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jeffrey L. Dage with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jeffrey L. Dage more than expected).

Fields of papers citing papers by Jeffrey L. Dage

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jeffrey L. Dage. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jeffrey L. Dage. The network helps show where Jeffrey L. Dage may publish in the future.

Co-authorship network of co-authors of Jeffrey L. Dage

This figure shows the co-authorship network connecting the top 25 collaborators of Jeffrey L. Dage. A scholar is included among the top collaborators of Jeffrey L. Dage based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jeffrey L. Dage. Jeffrey L. Dage is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Treatment‐related amyloid clearance (TRAC): a framework to characterize patients in the era of anti‐amyloid therapies 2025 ·Alzheimer s & Dementia ·Renaud La Joie, Jeffrey L. Cummings, Jeffrey L. Dage, Douglas Galasko, Miloš D. Ikonomović, Thomas K. Karikari, Susan Landau, Jorge J. Llibre‐Guerra, Catherine J. Mummery, Rik Ossenkoppele, Julie C. Price, Shannon L. Risacher, Ruben Smith, Christopher H. van Dyck, Marı́a C. Carrillo	2
2	Assessing Cognitive Decline and Dementia Risk in Black and White Older Adults With Blood Biomarkers pTau217, GFAP, NfL, and Aβ Ratio 2025 ·Neurology ·Ana W. Capuano, David A. Bennett, Jeffrey L. Dage, (unknown), Konstantinos Arfanakis, Melissa Lamar, Lisa L. Barnes, Julie A. Schneider	0
3	Plasma Biomarkers for Cerebral Amyloid Angiopathy and Implications for Amyloid-Related Imaging Abnormalities: A Comprehensive Review 2025 ·Journal of Clinical Medicine ·Mo‐Kyung Sin, Jeffrey L. Dage, Kwangsik Nho, N. Maritza Dowling, Nicholas T. Seyfried, David A. Bennett, Allan I. Levey, Ali Ahmed	3
4	Neuropathologic correlates of distinct plasma biomarker profiles in community-living older adults 2025 ·Brain ·Lei Yu, Lianlian Du, Tianhao Wang, Lisa L. Barnes, Jeffrey L. Dage, (unknown), Tatiana Foroud, David A. Bennett, Julie A. Schneider, Patricia A. Boyle	0
5	Association between BrainAGE and Alzheimer's disease biomarkers 2025 ·Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring ·(unknown), Rachael Deardorff, (unknown), (unknown), Jeffrey L. Dage, (unknown), (unknown), Jared R. Brosch, David A. Clark, Martin R. Farlow, Tatiana M. Foroud, Sujuan Gao, Sophia Wang, Henrik Zetterberg, Kaj Blennow, Andrew J. Saykin, Shannon L. Risacher	0
6	Storage-dependent variability in Alzheimer disease-related plasma biomarker results using the Fujirebio Lumipulse G1200 platform 2025 ·Journal of Neuropathology & Experimental Neurology ·Ibrahim Choucair, (unknown), Linda J. Van Eldik, Jeffrey L. Dage, Brian T. Gold, Erin L. Abner, Gregory A. Jicha, Peter T. Nelson	0
7	Risk of Alzheimer's disease is associated with longitudinal changes in plasma biomarkers in the multi‐ethnic Washington Heights–Hamilton Heights–Inwood Columbia Aging Project (WHICAP) cohort 2024 ·Alzheimer s & Dementia ·Yian Gu, Lawrence S. Honig, Min Suk Kang, (unknown), Danurys Sanchez, Dolly Reyes‐Dumeyer, Jennifer J. Manly, Jeffrey L. Dage, Rafael Lantigua, Adam M. Brickman, Badri N. Vardarajan, Richard Mayeux	11
8	Optimization of SHIP1 Inhibitors for the treatment of Alzheimer’s disease 2024 ·Alzheimer s & Dementia ·Cynthia D. Jesudason, Peter Bor‐Chian Lin, (unknown), (unknown), Audrey Lee‐Gosselin, Cynthia M. Ingraham, William L. Hamilton, (unknown), (unknown), (unknown), (unknown), Jerry Di Salvo, (unknown), Shaoyou Chu, Jeffrey L. Dage, Adrian L. Oblak, Timothy I. Richardson	1
9	Longitudinal cognitive trajectories in sporadic early‐onset Alzheimer’s Disease: Findings from LEADS 2024 ·Alzheimer s & Dementia ·Dustin B. Hammers, Ani Eloyan, (unknown), (unknown), Bonnie Wong, Jeffrey L. Dage, Kelly Nudelman, María C. Carrillo, Gil D. Rabinovici, Bradford C. Dickerson, Liana G. Apostolova	0
10	Safety, Tolerability, and Pharmacokinetics of Zagotenemab in Participants with Symptomatic Alzheimer’s Disease: A Phase I Clinical Trial 2023 ·Journal of Alzheimer s Disease Reports ·Brian A. Willis, Albert Lo, Jeffrey L. Dage, Sergey Shcherbinin, (unknown), Scott W. Andersen, Elizabeth LaBell, David Pérahia, Paula M. Hauck, Stephen L. Lowe	8
11	Blood-based biomarkers for Alzheimer’s disease: Current state and future use in a transformed global healthcare landscape breakdown → 2023 ·Neuron ·Harald Hampel, Yan Hu, Jeffrey L. Cummings, Soeren Mattke, Takeshi Iwatsubo, Akinori Nakamura, Bruno Vellas, Sid E. O’Bryant, Leslie M. Shaw, Min Cho, Richard Batrla, Andrea Vergallo, Kaj Blennow, Jeffrey L. Dage, Suzanne E. Schindler	121
12	Blood biomarkers for Alzheimer’s disease in clinical practice and trials breakdown → 2023 ·Nature Aging ·Oskar Hansson, Kaj Blennow, Henrik Zetterberg, Jeffrey L. Dage	196
13	Midpoint baseline results of the Longitudinal Early‐Onset Alzheimer’s Disease Study (LEADS) 2023 ·Alzheimer s & Dementia ·Dustin B. Hammers, Ani Eloyan, (unknown), (unknown), Laurel Beckett, Sujuan Gao, (unknown), Kelly Nudelman, Jeffrey L. Dage, Angelina J. Polsinelli, María C. Carrillo, Brad C. Dickerson, Gil D. Rabinovici, Liana G. Apostolova	1
14	Performance of plasma phosphorylated tau 181 and 217 in the community breakdown → 2022 ·Nature Medicine ·Michelle M. Mielke, Jeffrey L. Dage, Ryan D. Frank, Alicia Algeciras‐Schimnich, David S. Knopman, Val J. Lowe, Guojun Bu, Prashanthi Vemuri, Jonathan Graff‐Radford, Clifford R. Jack, Ronald C. Petersen	246
15	Plasma biomarkers of Alzheimer’s disease improve prediction of cognitive decline in cognitively unimpaired elderly populations breakdown → 2021 ·Nature Communications ·Nicholas Cullen, Antoine Leuzy, Shorena Janelidze, Sebastian Palmqvist, Anna L. Svenningsson, Erik Stomrud, Jeffrey L. Dage, Niklas Mattsson, Oskar Hansson	171
16	calcitonin gene-related peptide (CGRP) levels are elevated in the plasma and knee synovial fluid of patients with knee osteoarthritis (OA) 2016 ·Osteoarthritis and Cartilage ·(unknown), Xiyun Chai, (unknown), (unknown), (unknown), Karen L. Cox, Wesley H. Anderson, Peter G. Mitchell, (unknown), Jeffrey L. Dage, (unknown), K Johnson	2
17	Transcriptomic Analysis of Induced Pluripotent Stem Cells Derived from Patients with Bipolar Disorder from an Old Order Amish Pedigree 2015 ·PLoS ONE ·(unknown), Jiangang Liu, Rachelle J. Sells Galvin, Jeffrey L. Dage, Janice A. Egeland, Rosamund C. Smith, Kalpana Merchant, Steven M. Paul	26
18	Constitutive secretion of tau protein by an unconventional mechanism 2012 ·Neurobiology of Disease ·Xiyun Chai, Jeffrey L. Dage, Martin Citron	177
19	Application of LC/MS and related techniques to high-throughput drug discovery 2008 ·Drug Discovery Today ·Alfonso Espada, (unknown), Jeffrey L. Dage, Ming‐Shang Kuo	21
20	Investigation of retention behavior of drug molecules in supercritical fluid chromatography using linear solvation energy relationships 2008 ·Journal of Chromatography A ·Hai H. Bui, Thierry Masquelin, (unknown), (unknown), Jeffrey L. Dage, Ming‐Shang Kuo	32

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact